Background/Aims
To retrospectively compare conventional and drug-eluting beads transarterial
chemoembolization (C-TACE and DEB-TACE) for treatment of hepatocellular carcinoma
(HCC) at very early and early stages.
Methods
We retrospectively compared patients treated with C-TACE (n=115) or DEB-TACE
(n=103) from September 2009 to May 2016. All patients were in a very early (stage 0) or early
stage (stage A) of the Barcelona Clinic Liver Cancer (BCLC) staging system, and all had Child–
Pugh class A and ≤B7 liver status. Approval by the institutional review board was waived
because the study was retrospective. The following parameters were evaluated: severe pain
and bradycardia during TACE, post-embolization syndrome (PES), liver function change,
complications, target tumor response, and conversion to another treatment modality.
Numeric differences were assessed by the independent Student’s t-test for continuous
variables and by chi-square test for categorical variables.
Results
Severe intractable pain and bradycardia during the TACE procedure were significantly
more frequent in the C-TACE group than in the DEB-TACE group (P<0.001). The incidence and
duration of PES were significantly higher in the C-TACE group than in the DEB-TACE group
(P<0.001). The increase in liver enzymes was significantly higher in the C-TACE group than
in the DEB-TACE group (P<0.001). The deterioration of the Child-Pugh class was significantly
higher in the C-TACE group than in the DEB-TACE group (P =0.006). There was no significant
difference in serious complications except localized bile duct dilatation between the groups.
There was no significant difference between the groups in tumor response at both immediate
and 1-year assessment. The conversion rate to other treatment modalities was significantly
higher in the DEB-TACE group than in the C-TACE group (P<0.001).
Conclusions
DEB-TACE is better than C-TACE in terms of procedural safety as initial treatment
in a very early or early stage of HCC.